Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice.

Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice.
复制标题

DOI:
10.1186/1750-1326-9-42
复制
发表时间:
2014-10-26
影响因子:
15.1
通讯作者:
Vocadlo DJ
Vocadlo DJ
中科院分区:
医学1区
文献类型:
--
作者:
Yuzwa SA;Shan X;Jones BA;Zhao G;Woodward ML;Li X;Zhu Y;McEachern EJ;Silverman MA;Watson NV;Gong CX;Vocadlo DJ

文献摘要

参考文献

被引文献

相似文献

淀粉样斑块和神经纤维缠结(NFT)是阿尔茨海默病(AD)的病理学标志。在tau蛋白病小鼠模型中,增加细胞核和细胞质蛋白的O-连接的N-乙酰葡糖胺(O-GlcNAc)翻译后修饰的量减缓神经变性并阻断NFT的形成。然而,O-GlcNAc是否可以在tau病理学存在下影响淀粉样蛋白斑块的形成仍然是未知的。我们用一种高度选择性的口服生物可利用的酶抑制剂治疗了双转基因TAPP小鼠,该小鼠同时表达突变的人tau蛋白和淀粉样前体蛋白(APP),该酶负责清除O-GlcNAc(OGA)以增加脑中的O-GlcNAc。我们发现O-GlcNAc水平的增加阻断了TAPP小鼠的认知能力下降,这种作用与β-淀粉样肽水平的降低和淀粉样斑块水平的降低平行。该研究表明,在存在tau病理的情况下,增加的O-GlcNAc可以影响β-淀粉样蛋白病理。这些发现为OGA作为改变阿尔茨海默病疾病进展的有前途的治疗靶点提供了良好的支持。
Amyloid plaques and neurofibrillary tangles (NFTs) are the defining pathological hallmarks of Alzheimer’s disease (AD). Increasing the quantity of the O-linked N-acetylglucosamine (O-GlcNAc) post-translational modification of nuclear and cytoplasmic proteins slows neurodegeneration and blocks the formation of NFTs in a tauopathy mouse model. It remains unknown, however, if O-GlcNAc can influence the formation of amyloid plaques in the presence of tau pathology. We treated double transgenic TAPP mice, which express both mutant human tau and amyloid precursor protein (APP), with a highly selective orally bioavailable inhibitor of the enzyme responsible for removing O-GlcNAc (OGA) to increase O-GlcNAc in the brain. We find that increased O-GlcNAc levels block cognitive decline in the TAPP mice and this effect parallels decreased β-amyloid peptide levels and decreased levels of amyloid plaques. This study indicates that increased O-GlcNAc can influence β-amyloid pathology in the presence of tau pathology. The findings provide good support for OGA as a promising therapeutic target to alter disease progression in Alzheimer disease.
DOI: 10.1038/ng0692-218
发表时间: 1992-06-01
期刊: NATURE GENETICS
影响因子: 30.8
作者:
HENDRIKS, L;VANDUIJN, CM;VAN BROECKHOVEN, C
通讯作者: VAN BROECKHOVEN, C
DOI: 10.1016/s0006-291x(84)80190-4
发表时间: 1984-01-01
影响因子: 3.1
作者:
GLENNER, GG;WONG, CW
通讯作者: WONG, CW
DOI: 10.1073/pnas.121119298
发表时间: 2001-06-05
影响因子: 11.1
作者:
Alonso, AD;Zaidi, T;Iqbal, K
通讯作者: Iqbal, K
DOI: 10.1016/s0006-8993(02)04158-6
发表时间: 2003-03-21
期刊: BRAIN RESEARCH
影响因子: 2.9
作者:
Akimoto, Y;Comer, FI;Hart, GW
通讯作者: Hart, GW
DOI: 10.1038/nprot.2006.356
发表时间: 2006-01-01
期刊: NATURE PROTOCOLS
影响因子: 14.8
作者:
Kaech, Stefanie;Banker, Gary
通讯作者: Banker, Gary